Public Companies
IntelGenx Says Atai Life Sciences Collaboration Leads to Start of First-in-Human Clinical Study of Oral Thin Film Psychedelic Drug Candidate
IntelGenx Corp. (IGX.TO) on Thursday provided an update on its collaboration with its strategic partner, Atai Life Sciences (atai) for the development…
IntelGenx Corp. (IGX.TO) on Thursday provided an update on its collaboration with its strategic partner, Atai Life Sciences (atai) for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx’s polymeric film technologies.
Under the first of two current feasibility agreements between the companies, IntelGenx conducted pre-development, formulation development work and clinical supply manufacturing to provide a product prototype to Atai for further clinical investigation. The previously undisclosed candidate, buccal VLS-01, is a buccal film containing a synthetic form of N,N-dimethyltryptamine (DMT). Atai is developing the product as a therapy for treatment-resistant depression (TRD) along with Atai’s digital therapeutic designed to provide contextual “(mind)set-and-setting” support to patients before dosing.
dmt n-dimethyltryptamine dimethyltryptamine psychedelic therapy depression psychedelics atai atai life sciences“We were very pleased with Atai’s recent announcement that it had dosed the first subject in its Phase 1 clinical trial of buccal VLS-01, with topline results expected in H1 2023. The initiation of this first-in-human study of a pharmaceutical-grade psychedelic buccal film drug candidate represents the achievement of another major milestone for IntelGenx.”
Dr. Horst G. Zerbe, CEO of IntelGenx
New Study Suggests Childhood Trauma Doesn’t Cause Challenging Trips
Atai Life Sciences’ CEO Stepping Down
New Study Suggests Childhood Trauma Doesn’t Cause Challenging Trips
How To Participate in Psychedelic Clinical Trials
-
Psychedelics1 week agoNuminus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Law & Regulation1 week agoFDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week agoMindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week agoOptimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Law & Regulation1 week agoCompass Pathways keeps plugging away with its psilocybin study trials
-
Psilocybin1 week agoOregon authorities give Kaya Holdings license for psilocybin treatment clinic
-
Ketamine1 week agoClinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update